ESSA Pharma IncNASDAQ:EPIX
- LAST PRICE6.6200
- TODAY'S CHANGE (%)0.1900 (2.9549%)
- Bid / Lots6.7500/ 2
- Ask / Lots8.2800/ 1
- Open / Previous Close6.4600 / 6.4300
- Day Range
- 52 Week Range
- Volume36,659
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EPIX |
|---|---|---|
| 09:32 ET | 1035 | 6.46 |
| 09:54 ET | 200 | 6.66 |
| 10:01 ET | 400 | 6.53 |
| 10:12 ET | 100 | 6.58 |
| 10:26 ET | 200 | 6.78 |
| 10:30 ET | 500 | 7.04 |
| 10:33 ET | 500 | 6.94 |
| 10:35 ET | 143 | 6.896 |
| 10:37 ET | 499 | 6.9999 |
| 10:53 ET | 500 | 6.984 |
| 11:02 ET | 100 | 6.99 |
| 11:04 ET | 286 | 6.89 |
| 11:11 ET | 1310 | 6.78 |
| 11:29 ET | 750 | 6.9621 |
| 11:36 ET | 800 | 6.75 |
| 02:38 ET | 5524 | 6.77 |
| 02:40 ET | 100 | 6.71 |
| 02:42 ET | 100 | 6.69 |
| 02:44 ET | 400 | 6.6 |
| 02:45 ET | 200 | 6.59 |
| 02:51 ET | 800 | 6.75 |
| 02:54 ET | 900 | 6.75 |
| 03:03 ET | 100 | 6.755 |
| 03:12 ET | 400 | 6.73 |
| 03:14 ET | 100 | 6.75 |
| 03:16 ET | 300 | 6.75 |
| 03:18 ET | 100 | 6.75 |
| 03:39 ET | 200 | 6.7 |
| 03:56 ET | 1057 | 6.6942 |
| 03:57 ET | 200 | 6.625 |
| 03:59 ET | 12556 | 6.62 |
Apr 9, 2024
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ESSA Pharma Inc | 284.5M | -11.3x | --- |
Acrivon Therapeutics Inc | 280.6M | -3.0x | --- |
Black Diamond Therapeutics Inc | 292.6M | -3.1x | --- |
Inovio Pharmaceuticals Inc | 290.0M | -1.9x | --- |
Inozyme Pharma Inc | 272.4M | -3.3x | --- |
Zura Bio Ltd | 271.9M | -0.9x | --- |
Company Information
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Contact Information
- Headquarters
- 999 West Broadway, Suite 720VANCOUVER, BC, Canada V5Z 1K5
- Phone
- 778-331-0962
- Fax
- 778-331-0962
Executives
- Non-Executive Independent Chairman of the Board
- Richard Glickman
- President, Chief Executive Officer, Director
- David Parkinson
- Chief Financial Officer
- David Wood
- Chief Operating Officer, Executive Vice President
- Peter Virsik
- Executive Vice President, Chief Medical Officer
- Alessandra Cesano
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $284.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 44.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.75 |
EPS | $-0.59 |
Book Value | $3.30 |
P/E Ratio | -11.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
